Peroral IMUNOR, a low-molecular-weight immunomodulator prepared from disintegrated and ultrafiltered leukocytes, enhances recovery from myelosuppression induced by cisplatin or 5-fluorouracil
Language English Country Great Britain, England Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
16684664
DOI
10.1080/08923970600623525
PII: J17033845131274P
Knihovny.cz E-resources
- MeSH
- Bone Marrow Cells drug effects immunology MeSH
- Cisplatin * MeSH
- Fluorouracil * MeSH
- Granulocytes drug effects immunology MeSH
- Hematopoiesis drug effects MeSH
- Immunologic Factors chemistry pharmacology MeSH
- Stem Cells drug effects MeSH
- Leukocytes chemistry immunology MeSH
- Mice, Inbred ICR MeSH
- Mice MeSH
- Bone Marrow Diseases chemically induced drug therapy MeSH
- Swine MeSH
- Antimetabolites, Antineoplastic * MeSH
- Antineoplastic Agents * MeSH
- Ultrafiltration MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Cisplatin * MeSH
- Fluorouracil * MeSH
- Immunologic Factors MeSH
- Antimetabolites, Antineoplastic * MeSH
- Antineoplastic Agents * MeSH
A single dose of IMUNOR, a low-molecular-weight immunodulator prepared from disintegrated and ultrafiltered pig leukocytes, was found to enhance recovery of murine pool of hemopoietic progenitor cells for granulocytes and macrophages damaged by a single injection of cytotoxic drugs 5-fluorouracil or cisplatin. The best results were obtained after the treatment with IMUNOR on days 3 or 4 after the injection of 5-fluorouracil or cisplatin. These results together with previous findings obtained in our laboratory suggest that IMUNOR has the potential to become a part of treatment schemes in oncological practice aimed at alleviation of myelosuppression evoked by cytotoxic anti-tumor therapy.
References provided by Crossref.org
